Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Research Models
ApoE4 (Δ272-299)and (Δ241-299)

Posted 22 May 2005

General Information

Transgene: PCR products encoding human apoE4 (Δ272-299) or apoE4 (Δ241-299), both with a signal peptide for secretion and a FLAG tag at the amino terminus, were subcloned into a Thy-1.2 vector. Transgenic mice expressing apoE4 (Δ272-299) or apoE4 (Δ241-299) were generated by microinjecting these DNA constructs into C57BL/6J mouse eggs. All hemizygous transgenic mice were on a pure C57BL/6J background and still expressed endogenous mouse apoE.

Promoter: Neuron-specific Thy-1.2

Mouse strain: Origin: C57BL/6J; Backcrossed with murine apoE-null mice, N>6

Phenotype

Neuropathological analysis

Mice still expressed endogenous mouse apoE. Transgenic mice expressing the carboxyl-terminal-cleaved product, apoE4 (Δ272-299), at high levels in the brain died at 2-4 months of age. The cortex and hippocampus of these mice displayed AD-like neurodegenerative alterations, including abnormally phosphorylated tau (p-tau) and Gallyas silver-positive neurons that contained cytosolic straight filaments with diameters of 15-20 nm, resembling preneurofibrillary tangles. Transgenic mice expressing lower levels of the truncated apoE4 survived longer but showed impaired learning and memory at 6-7 months of age.

Behavioral

Transgenic mice expressing lower levels of apoE4 (Δ272-299) were viable and fertile.

Availability

Licensing/academic distribution contact information:

Yadong Huang
Gladstone Institute of Neurological Disease
1650 Owens Street
San Francisco, CA 94158
Phone: 415-734-2511
Fax: 415-355-0824
Email: yhuang@gladstone.ucsf.edu

Patents: Patent Number: US678751982; Title: Methods of Treating disorders Related to ApoE; Inventors: UCSF/Huang, Y. and Mahley, R.W.; Filing Date: 11/02/2001; Issue Date: 09/07/2004

References

Primary:

Harris F M, Brecht W J, Xu O, Tesseur I , Kekonius L , Wyss-Coray T , Fish J D, Masliah E , Hopkins P C , Scearce-Levie K , Weisgraber K H, Mucke L , Mahley R W and Huang Y. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci. 100: 10966-10971, 2003 Abstract.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark

See recent updates
Alzheimer's Disease Mouse Model Resource
Considerations for Choosing Controls
Research Tools

Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad